Skip to Content

Notice

Manufacturer of Controlled Substances; Notice of Application

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 16, 2009, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

DrugSchedule
Cathinone (1235)I
Methcathinone (1237)I
N-Ethylamphetamine (1475)I
N,N-Dimethylamphetamine (1480)I
Aminorex (1585)I
4-Methylaminorex (cis isomer) (1590)I
Gamma-Hydroxybutyric acid (2010)I
Methaqualone (2565)I
Alpha-ethyltryptamine (7249)I
Lysergic acid diethylamide (7315)I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348)I
Marihuana (7360)I
Tetrahydrocannabinols (7370)I
Mescaline (7381)I
3,4,5-Trimethoxyamphetamine (7390)I
4-Bromo-2,5-dimethoxyamphetamine (7391)I
4-Bromo-2,5-dimethoxyphenethylamine (7392)I
4-Methyl-2,5-dimethoxyamphetamine (7395)I
2,5-Dimethoxyamphetamine (7396)I
2,5-Dimethoxy-4-ethylamphetamine (7399)I
3,4-Methylenedioxyamphetamine (7400)I
5-Methoxy-3,4-methylenedioxyamphetamine (7401)I
N-Hydroxy-3,4-methylendioxyamphetamine (7402)I
3,4-Methylendioxy-N-ethylamphetamine (7404)I
3,4-Methylenedioxymethamphetamine (7405)I
4-Methoxyamphetamine (7411)I
Alpha-methyltryptamine (7432)I
Bufotenine (7433)I
Diethyltryptamine (7434)I
Dimethyltryptamine (7435)I
Psilocybin (7437)I
Psilocyn (7438)I
5-Methoxy-N,N-diisopropyltyptamine (7439)I
N-Benzylpiperazine (7493)I
Acetyldihydrocodeine (9051)I
Benzylmorphine (9052)I
Codeine-N-oxide (9053)I
Dihydromorphine (9145)I
Start Printed Page 69465
Heroin (9200)I
Hydromorphinol (9301)I
Methyldihydromorphine (9304)I
Morphine-N-oxide (9307)I
Normorphine (9313)I
Pholcodine (9314)I
Acetylmethadol (9601)I
Allylprodine (9602)I
Alphacetylmethadol except levo-alphacetylmethadol (9603)I
Alphameprodine (9604)I
Alphamethadol (9605)I
Betacetylmethadol (9607)I
Betameprodine (9608)I
Betamethadol (9609)I
Betaprodine (9611)I
Hydroxypethidine (9627)I
Noracymethadol (9633)I
Norlevorphanol (9634)I
Normethadone (9635)I
Trimeperidine (9646)I
Phenomorphan (9647)I
1-Methyl-4-phenyl-4-propionoxypiperidine (9661)I
Tilidine (9750)I
Para-Fluorofentanyl (9812)I
3-Methylfentanyl (9813)I
Alpha-Methylfentanyl (9814)I
Acetyl-alpha-methylfentanyl (9815)I
Beta-hydroxyfentanyl (9830)I
Beta-hydroxy-3-methylfentanyl (9831)I
Alpha-Methylthiofentanyl (9832)I
3-Methylthiofentanyl (9833)I
Thiofentanyl (9835)I
Amphetamine (1100)II
Methamphetamine (1105)II
Lisdexamfetamine (1205)II
Phenmetrazine (1631)II
Methylphenidate (1724)II
Amobarbital (2125)II
Pentobarbital (2270)II
Secobarbital (2315)II
Glutethimide (2550)II
Nabilone (7379)II
1-Phenylcyclohexylamine (7460)II
Phencyclidine (7471)II
1-Piperidinocyclohexanecarbonitrile (8603)II
Alphaprodine (9010)II
Cocaine (9041)II
Codeine (9050)II
Dihydrocodeine (9120)II
Oxycodone (9143)II
Hydromorphone (9150)II
Diphenoxylate (9170)II
Benzoylecgonine (9180)II
Ethylmorphine (9190)II
Hydrocodone (9193)II
Levomethorphan (9210)II
Levorphanol (9220)II
Isomethadone (9226)II
Meperidine (9230)II
Meperidine intermediate-A (9232)II
Meperidine intermediate-B (9233)II
Meperidine intermediate-C (9234)II
Methadone (9250)II
Methadone intermediate (9254)II
Dextropropoxyphene, bulk (non-dosage forms) (9273)II
Morphine (9300)II
Thebaine (9333)II
Levo-alphacetylmethadol (9648)II
Oxymorphone (9652)II
Noroxymorphone (9668)II
Racemethorphan (9732)II
Alfentanil (9737)II
Sufentanil (9740)II
Tapentadol (9780)II
Start Printed Page 69466
Fentanyl (9801)II

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than January 11, 2011.

Start Signature

Dated: November 1, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

End Signature End Preamble

[FR Doc. 2010-28516 Filed 11-10-10; 8:45 am]

BILLING CODE 4410-09-P